CTOs on the Move

The Carolinas Center for Medical Excellence (CCM

www.mrnc.org

 
The Carolinas Center for Medical Excellence (CCME) is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mrnc.org
  • 100 Regency Forest Dr Ste 200
    Cary, NC USA 27518
  • Phone: 919.380.9860

Executives

Name Title Contact Details

Similar Companies

Nature`s Sunshine

Nature`s Sunshine Products manufactures and markets tablets and encapsulated herbal products, high-quality natural vitamins, food supplements, skin care and other complementary products. The Company has operations in the United States, South Korea, Mexico, Venezuela, Japan, Brazil, Canada, Central America, Colombia, Ecuador, Peru, the United Kingdom, Israel and Chile. The Company also exports its products to several other countries, including Argentina, Australia, Malaysia, New Zealand, Norway and the Russian Federation.

Avamere

Avamere Family of Companies, a group of independent privately owned post-acute care companies, is dedicated to seniors` health and well-being. We take great pride in offering a continuum of care, which allows seniors to stay independent and active.

Invatec

Invatec is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FORME

At Forme, we specialize in designing and manufacturing innovative and high-quality health and wellness products. Our extensive range includes sports nutrition, weight loss supplements, and vitamins to support overall wellbeing. We are dedicated to prov...

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.